Theophylline for Depression Study

Theophylline for Depression Study

Publication date: Mar 16, 2020

Depression is very common and poses a huge disease burden. About 20% of the US population suffers from depression at least once in their lifetime. Inflammations that are hidden inside our body as a result of aging, obesity, chronic diseases, or certain treatments (e.g., interferon for hepatitis C) appear to cause depressive symptoms and even clinical depression. Individuals with such inflammations are more likely to suffer from depression and are less likely to respond to currently available antidepressant medications. This study will test theophylline, a medication currently used for asthma treatment, as a new way to mitigate depressive symptoms in response to such inflammations. This study begins with a 90-minute screening session to determine whether participants are eligible to join the main study. Those who meet the eligibility criteria will then join the main study, which will consist of taking theophylline or methylcellulose (i.e., oral placebo) for 2 weeks at home and an 8-hour session at the UCLA Medical Center. Approximately 20 healthy adults will be recruited for participation in the study. During the course of the study, participants will take theophylline or methylcellulose for 2 weeks at home and then will be injected either lipopolysaccharide (LPS) or saline (i.e., intravenous placebo) at the UCLA Medical Center. LPS is a bacterial substance that can initiate chemical reactions that are similar to those seen in individuals with mild sickness symptoms, such as a slight increase in body temperature, muscle aches, or tiredness. It is a safe way of investigating the body’s response to inflammation and how these changes may alter cognitive, emotional, or neural function. It has been given thousands of times to healthy volunteers – both younger and older adults – without any serious side effects.

Concepts Keywords
Aging Psychiatric disorders
Analgesics Depression
Antidepressant Major depressive disorder
Asthma Anti inflammatory drugs
Axis Body s inflammation
Birth Control G interferon hepatitis
Body Temperature Birth control
Breastfeeding Branches of biology
Caffeine Depression
California Medicine
Cardiovascular Disease Neuroscience
Chronic Diseases Psychiatric diagnosis
Clinical Depression Phosphodiesterase inhibitors
Cognitive Xanthines
Contraindication Abnormal psychology
Cytokine Theophylline
Depression Major depressive disorder
ECG Caffeine
Electrocardiogram
Hepatic Impairment
Hepatitis
Hypersensitivity
Inflammation
Interferon
Intravenous
Lipopolysaccharide
Los Angeles
LPS
Major Depressive Disorder
Methylcellulose
Muscle Aches
Obesity
Opioid
Peptic Ulcer Disease
Placebo
Pregnancy
Psychiatric Disorders
Psychotropics
Recreational Drug
Saline
Seizure Disorders
Smoking
Steroid
Steroids
Theophylline
UCLA
Urine Test
Xanthine Derivatives

Semantics

Type Source Name
drug DRUGBANK Theophylline
disease MESH Depression
disease MESH Inflammations
disease MESH aging
disease MESH obesity
disease MESH chronic diseases
disease MESH hepatitis C
pathway KEGG Hepatitis C
disease MESH asthma
pathway KEGG Asthma
drug DRUGBANK Methylcellulose
disease MESH hypersensitivity
drug DRUGBANK Xanthine
disease MESH contraindication
disease MESH cardiovascular disease
disease MESH peptic ulcer
disease MESH seizure disorders
disease MESH psychiatric disorders
disease MESH major depressive disorder
drug DRUGBANK Caffeine
disease MESH abnormalities

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *